Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Guillain-Barré syndrome: clinical profile and management.
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Daclizumab (anti-CD25) in multiple sclerosis.
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Fingolimod modulates microglial activation to augment markers of remyelination.
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.

Pages